| Stanley R Easterling, MD | |
|
104 Mcauley Dr, Vicksburg, MS 39183-2825 | |
| (601) 638-7271 | |
| Not Available |
| Full Name | Stanley R Easterling |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 104 Mcauley Dr, Vicksburg, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154359818 | NPI | - | NPPES |
| 1383872 | Medicaid | LA | |
| 00114107 | Medicaid | MS | |
| 4216184 | Other | MS | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 10687 (Mississippi) | Primary |
| Entity Name | Vicksburg Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790711158 PECOS PAC ID: 5890696330 Enrollment ID: O20040116000738 |
News Archive
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
Cold Spring Harbor Laboratory scientists have developed a new model for assessing kidney function in cancer patients as part of an international collaboration that involved contributions from the United Kingdom and Sweden.
Community Health Systems, Inc. announced today that subsidiaries of the Company have completed the divestiture of five Pennsylvania hospitals and their associated assets to subsidiaries of Reading Health System.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
› Verified 4 days ago
| Entity Name | Pathway Healthcare- Columbus Ms Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245755990 PECOS PAC ID: 4385903905 Enrollment ID: O20180104001883 |
News Archive
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
Cold Spring Harbor Laboratory scientists have developed a new model for assessing kidney function in cancer patients as part of an international collaboration that involved contributions from the United Kingdom and Sweden.
Community Health Systems, Inc. announced today that subsidiaries of the Company have completed the divestiture of five Pennsylvania hospitals and their associated assets to subsidiaries of Reading Health System.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
› Verified 4 days ago
| Entity Name | Pathway Healthcare- Mississippi Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013425503 PECOS PAC ID: 3779844774 Enrollment ID: O20180308001891 |
News Archive
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
Cold Spring Harbor Laboratory scientists have developed a new model for assessing kidney function in cancer patients as part of an international collaboration that involved contributions from the United Kingdom and Sweden.
Community Health Systems, Inc. announced today that subsidiaries of the Company have completed the divestiture of five Pennsylvania hospitals and their associated assets to subsidiaries of Reading Health System.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
› Verified 4 days ago
| Entity Name | Pathway Healthcare - Jackson, Ms, Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487179156 PECOS PAC ID: 1052674439 Enrollment ID: O20180417002749 |
News Archive
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
Cold Spring Harbor Laboratory scientists have developed a new model for assessing kidney function in cancer patients as part of an international collaboration that involved contributions from the United Kingdom and Sweden.
Community Health Systems, Inc. announced today that subsidiaries of the Company have completed the divestiture of five Pennsylvania hospitals and their associated assets to subsidiaries of Reading Health System.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stanley R Easterling, MD 1000 Urban Center Dr, Ste 600, Vestavia, AL 35242-2584 Ph: (601) 638-7271 | Stanley R Easterling, MD 104 Mcauley Dr, Vicksburg, MS 39183-2825 Ph: (601) 638-7271 |
News Archive
The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo.
Cold Spring Harbor Laboratory scientists have developed a new model for assessing kidney function in cancer patients as part of an international collaboration that involved contributions from the United Kingdom and Sweden.
Community Health Systems, Inc. announced today that subsidiaries of the Company have completed the divestiture of five Pennsylvania hospitals and their associated assets to subsidiaries of Reading Health System.
FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
› Verified 4 days ago
Dr. Robert C Masterson, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Mission 66, Vicksburg, MS 39180 Phone: 601-636-8244 | |
Carlos Alberto Latorre, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Mission 66, Vicksburg, MS 39180 Phone: 601-636-0097 | |
George Abraham, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1907 Mission 66, Vicksburg, MS 39180 Phone: 601-619-3838 | |
John R Barnes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Mission 66, Vicksburg, MS 39180 Phone: 601-636-0097 Fax: 601-629-9969 | |
Dr. Robert Michael Cannon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1901 Mission 66, Vicksburg, MS 39180 Phone: 601-636-0097 Fax: 601-629-9969 | |
Breanna Heard-pinho, Family Medicine Medicare: Medicare Enrolled Practice Location: 1901 Mission 66, Vicksburg, MS 39180 Phone: 601-636-1050 Fax: 601-631-2337 |